Léon Bérard Cancer Center, Lyon, France.
University of Lyon, Villeurbanne, France.
Integr Cancer Ther. 2021 Jan-Dec;20:1534735420977666. doi: 10.1177/1534735420977666.
Exercise has been shown to improve physical and psychological conditions during cancer therapy, but mechanisms remain poorly understood. The purpose of the present study was to report the results of cancer-related biomarkers and metabolomics outcomes from the PASAPAS feasibility study.
In the PASAPAS randomized controlled trial, 61 women beginning adjuvant chemotherapy for localized breast cancer were randomized in a 6-month program of weekly aerobic exercises associated with nutritional counseling versus usual care with nutritional counseling. In the present analysis of 58 women for whom blood samples were available, first, circulating levels of biomarkers (ie, insulin, insulin-like growth factor 1, estradiol, adiponectin, leptin, interleukin-6, and tumor necrosis factor α) were measured at baseline and 6-month follow-up. Changes in biomarkers were compared between exercisers (n = 40) and controls (n = 18) using mixed-effect models. Second, serum metabolites were studied using an untargeted H nuclear magnetic resonance spectroscopy, and orthogonal partial least squares analyses were performed to discriminate exercisers and controls at baseline and at 6 months.
Over the 6-month intervention, no statistically significant differences were observed between exercisers and controls regarding changes in biomarkers and metabolomic profiles.
The present analysis of the PASAPAS feasibility trial did not reveal any improvement in circulating biomarkers nor identified metabolic signatures in exercisers versus controls during adjuvant breast cancer treatment. Larger studies preferably in women with poor physical activity level to avoid ceiling effect, testing different doses and types of exercise on additional biological pathways, could allow to clarify the mechanisms mediating beneficial effects of physical exercise during cancer treatment.
ClinicalTrials.gov Identifier: NCT01331772. Registered 8 April 2011, https://clinicaltrials.gov/ct2/show/NCT01331772?term=pasapas&rank=1.
运动已被证明可改善癌症治疗期间的身体和心理状况，但机制仍知之甚少。本研究的目的是报告 PASAPAS 可行性研究中与癌症相关的生物标志物和代谢组学结果。
在 PASAPAS 随机对照试验中，61 名开始接受局部乳腺癌辅助化疗的女性被随机分配到为期 6 个月的每周有氧运动方案中，该方案与营养咨询相结合，与常规护理和营养咨询进行比较。在本分析中，对 58 名可获得血液样本的女性进行了分析，首先，在基线和 6 个月随访时测量了循环生物标志物（即胰岛素、胰岛素样生长因子 1、雌二醇、脂联素、瘦素、白细胞介素 6 和肿瘤坏死因子 α）的水平。使用混合效应模型比较了锻炼者（n=40）和对照组（n=18）之间的生物标志物变化。其次，使用非靶向 H 核磁共振波谱法研究血清代谢物，并进行正交偏最小二乘分析，以在基线和 6 个月时区分锻炼者和对照组。
在 6 个月的干预过程中，锻炼者和对照组之间在生物标志物和代谢组学特征的变化方面没有观察到统计学上的显著差异。
本研究对 PASAPAS 可行性试验的分析并未显示在辅助乳腺癌治疗期间，与对照组相比，运动者的循环生物标志物或代谢特征有任何改善。更大规模的研究，最好是在身体活动水平较差的女性中进行，以避免天花板效应，测试不同剂量和类型的运动对其他生物学途径的影响，可能有助于阐明运动对癌症治疗有益影响的机制。
ClinicalTrials.gov 标识符：NCT01331772。于 2011 年 4 月 8 日注册，https://clinicaltrials.gov/ct2/show/NCT01331772?term=pasapas&rank=1。
